Greenlight Guru Alternative for Medical Device QMS and Regulatory Readiness

What Greenlight Guru Is Known For

Greenlight Guru describes its QMS software as built for medtech. Its public QMS page describes workflows such as:

• Document control
• Change management
• Training management
• Supplier management
• Quality events
• Parts and BOM
• Risk management
• CAPA and nonconformance
• Audit management
• Design controls and DHF

That makes it most relevant to device companies that need medtech-specific quality management. For a team that is building or replacing its core QMS, those workflows matter. Device companies need a controlled operating system for product development, production, supplier oversight, postmarket signals, corrective action, and inspection response.

Greenlight Guru's public materials emphasize quality and product records in a medtech-focused system. Teams comparing alternatives should therefore ask whether they are replacing a QMS workflow, adding a regulatory evidence layer, or solving a specific submission-readiness problem.

That distinction prevents a poor buying decision. If the company needs complaint handling, supplier quality, CAPA, nonconformance, document control, and DHF execution in one medtech QMS, the evaluation should be QMS-first. If the company already has quality records but cannot map them to FDA submission questions, the evaluation should focus on evidence readiness, regulatory impact, and source-record traceability.

The QMSR and eSTAR Context

FDA's Quality Management System Regulation, or QMSR, became effective on February 2, 2026. FDA states that QMSR amends device CGMP requirements in 21 CFR Part 820 and incorporates ISO 13485:2016 by reference. FDA also states that it began using an updated medical device manufacturer inspection program on the QMSR effective date.

That matters for software evaluation because the question is no longer only whether a system has familiar legacy module names. The question is whether the company can operate and retrieve controlled evidence for the quality management system it actually uses.

For submissions, FDA's eSTAR program creates a separate but connected pressure. FDA describes eSTAR as an interactive PDF form that guides applicants through preparing a comprehensive medical device submission. FDA states that eSTAR is required for 510(k) submissions and De Novo submissions unless exempted, while it is voluntary for several other device submission types.

eSTAR does not replace QMS software. It also does not prove QMSR compliance. It creates a structured submission workspace that still depends on controlled source evidence. If the source records are scattered, draft, superseded, or inconsistent, the eSTAR package becomes harder to defend.

What Problem Are You Actually Solving?

Before comparing vendors, define the buying problem in plain language.

If most of the pain is in the first row, a mature medtech QMS-first tool may be the right anchor. If the pain is concentrated in the last four rows, the team should evaluate whether a regulatory-readiness layer around existing source records is the better first move.

When Teams Look for Alternatives

Common reasons include:

• Need for stronger regulatory submission preparation
• Need to connect QMS evidence to eSTAR sections
• Desire for a lighter tool around regulatory readiness
• Need for QMS + RIM convergence
• Existing QMS already in place, but submission evidence is fragmented
• Budget, implementation, or workflow fit concerns

Not every team looking for an alternative wants a full eQMS replacement. Some want a regulatory readiness layer around existing quality records. Others want a more focused implementation because they are preparing for a specific FDA milestone and cannot wait for a broad system rollout.

That difference changes the buying process. If quality operations owns the pain, the evaluation should focus on design controls, CAPA, training, suppliers, complaints, audits, and QMSR workflows. If regulatory owns the pain, the evaluation should focus on eSTAR evidence mapping, 510(k) decision support, submission section readiness, and traceability from source records to regulatory claims.

When Greenlight Guru May Be the Better Fit

Greenlight Guru may be a better fit when the company needs a medtech QMS system of record and the core workflows are quality-led. Examples include:

• The company is implementing its first controlled device QMS.
• Quality owns document control, training, CAPA, supplier quality, complaints, and audits.
• The team needs device-specific workflows rather than a generic QMS.
• Design controls and DHF execution are central to the buying decision.
• The organization wants quality operations, product records, and postmarket signals in one QMS-first environment.
• The company needs a mature quality execution workflow more than a submission evidence layer.

In these scenarios, the evaluation should be direct and detailed. Ask the vendor to show the workflow, not only the module list. A QMS demo should prove that a real device quality event can move through intake, investigation, risk assessment, CAPA, change control, training, approval, closure, reporting, and inspection retrieval.

When a Greenlight Guru Alternative May Make Sense

An alternative may make sense when the team is not primarily trying to replace Greenlight Guru or another eQMS. The team may instead need a workflow around regulatory evidence.

Common examples include:

• The company already has an eQMS, but regulatory teams still rebuild submission evidence manually.
• A 510(k), De Novo, PMA, or eSTAR package is delayed because approved source records are hard to find.
• Design, risk, verification, validation, software, and labeling records exist but do not map cleanly to submission sections.
• Change controls do not clearly document regulatory impact across products, markets, or prior submissions.
• Regulatory teams need to know whether a quality record has been used in a prior filing or health authority response.
• The team wants to start with submission readiness before changing the core QMS.

This is where the phrase "alternative" can be misleading. The right answer may be a replacement, but it may also be a complement. A team can keep its QMS as the system of record and use a separate regulatory-readiness workflow to organize, review, and reuse approved evidence.

What to Compare

The key is not whether a vendor says "yes" to a category. The key is whether the system can show the evidence trail in a realistic scenario.

Evaluation Scenarios

Ask vendors to show:

1. A design input changes and the team must update risk, verification, and DHF evidence.
2. A complaint trend creates CAPA and possible regulatory reporting review.
3. A supplier change affects a critical component and may affect submission evidence.
4. A software change affects cybersecurity, performance, or risk controls.
5. A 510(k) or eSTAR package needs approved source evidence by section.
6. A quality record used in a prior submission changes later.
7. A labeling claim changes and the team must verify that risk, performance, usability, and instructions-for-use evidence still support it.
8. A test report is revised after a submission draft already cited the earlier version.
9. A CAPA changes a manufacturing control and the team must decide whether a new submission, notification, or internal record update is needed.
10. FDA asks for clarification and the response team needs source evidence within days, not weeks.

The last two scenarios are where regulatory readiness tooling can be especially valuable. They test whether the system can show not only that a record exists, but where it is used and what regulatory context it affects.

Evidence That Matters for eSTAR Readiness

For medical device teams, submission readiness usually depends on more than a document repository. The regulatory team needs approved evidence that supports the device story.

Typical evidence includes:

• Device description and configuration records
• Intended use and indications for use support
• Design input, output, review, verification, and validation evidence
• Risk management files and risk-control verification
• Software requirements, architecture, testing, anomalies, cybersecurity, and release records
• Biocompatibility, sterilization, shelf-life, packaging, and performance evidence where applicable
• Labeling, IFU, warnings, symbols, and claims support
• Supplier, component, manufacturing, and process evidence
• Complaint, CAPA, nonconformance, and postmarket evidence where relevant

The regulatory question is not simply "does this record exist?" It is:

• Is this the approved version?
• Does it match the device configuration in the submission?
• Does it support the claim being made?
• Has it changed since a prior submission or agency response?
• Does the change require a new regulatory assessment?

That is the gap many teams feel when they say their QMS is not enough for submission readiness.

Where Assyro Helps

Assyro helps medical device teams organize regulatory evidence for FDA submissions. Teams can connect quality records to eSTAR, 510(k), De Novo, and PMA readiness, especially when quality records already exist in another system but are hard to reuse during submission preparation.

For device teams, the practical goal is to keep quality evidence connected to regulatory use. That includes mapping design, risk, verification, validation, software, labeling, supplier, complaint, CAPA, and change records to eSTAR sections and future lifecycle decisions.

Assyro is not a substitute for a manufacturer's quality system procedures, responsibilities, training, validation, or QMSR implementation. Its role is more specific: make regulated source evidence easier to find, review, connect, and reuse when regulatory teams need to prepare submissions, answer health authority questions, or document impact decisions.

That distinction is important. A team with no controlled QMS still needs controlled quality execution. A team with a QMS but weak evidence traceability may need a regulatory-readiness layer.

Best Fit Scenarios

Assyro is a stronger fit when:

• The immediate problem is submission evidence organization.
• Regulatory teams need to connect quality records to eSTAR.
• Quality records need to connect to regulatory application and submission context.
• The team is lean and needs practical regulatory workflow support.
• The company already has QMS records but still manages submission evidence in spreadsheets, folders, or manual trackers.
• Change controls need clearer regulatory impact assessment.

A mature medtech eQMS may be a stronger fit when:

• The company needs full device QMS execution today.
• The main pain is DHF, design controls, CAPA, audits, or supplier workflows.
• Quality operations owns the buying process.
• The company needs a system of record for daily quality workflows, not only submission evidence.

How to Choose

Choose a medtech QMS-first tool when the immediate need is day-to-day quality execution: design controls, DHF, CAPA, supplier quality, complaints, audits, and training.

Choose a regulatory-readiness layer when the immediate pain is mapping controlled quality and design evidence to eSTAR, 510(k), De Novo, PMA, or health authority response work.

Use this decision rule:

• If the source records are not controlled, fix QMS execution first.
• If the source records are controlled but hard to reuse for regulatory work, fix evidence traceability.
• If device changes are closing without clear filing impact decisions, fix regulatory impact assessment.
• If submissions are delayed because teams cannot find approved evidence, fix submission readiness.
• If both quality execution and regulatory evidence are weak, sequence the work by the next business-critical milestone.

Some teams may use both: a QMS for source records and Assyro for regulatory evidence readiness. That can be more practical than forcing one system to solve every quality, product, regulatory, and submission workflow at once.

Mistakes to Avoid

• Treating a vendor comparison as a feature checklist without testing real records.
• Assuming eSTAR readiness exists because the QMS has document control.
• Moving to a new QMS before defining record ownership, migration scope, validation needs, and inspection retrieval expectations.
• Ignoring software, cybersecurity, labeling, and supplier evidence until submission writing begins.
• Using uncontrolled exports from the QMS as submission evidence.
• Closing change controls without documenting regulatory impact and affected submission context.
• Buying a broad QMS when the urgent problem is narrower submission evidence readiness.
• Buying a submission-readiness tool when the company still lacks controlled quality execution.

Related Reading

• From QMSR to eSTAR
• eSTAR submission software guide
• Medical device QMS software guide
• Quality-to-regulatory traceability

References

This comparison is based on public vendor materials as of May 2026 and is not procurement advice.